Dak

[Dak @dakmonster46]

@danielbroukhim @Lucie_Health I like it

[Daniel Broukhim @danielbroukhim]

1️⃣ $OSCR just launched @Lucie_Health — the Airbnb of health insurance.

A consumer-first marketplace where Americans can shop, compare, and buy health coverage the way they book a vacation home.

This is the storefront for the future of healthcare. But the real story today? The glaring valuation mismatch. 🧵👇

[Chamath Palihapitiya @chamath]

Just do things.

[Vlad Tenev @vladtenev]

Mortgage benefits are now live for all eligible annual Robinhood Gold subscribers. Get access to some of the lowest mortgage rates on the market and $500 off closing costs, powered by Sage Home Loans.

The response to our pilot was incredible and we can’t wait to make homeownership more accessible 🏡

[Reasonably Approximating 🇺🇸 🇺🇦 🔋 🅰️ @bert_gilfoyle]

Short report discusses old news from stress testing at Edison. And nobody knows the backlog better than us. Debunked.

[First Squawk @FirstSquawk]

AI DATA CENTERS WILL QUADRUPLE GLOBAL POWER DEMAND IN THE NEXT 10 YEARS

Battery storage led by $TSLA & $EOSE will stabilize the grid by storing excess generation and discharging during peak inference cycles.

[Sleuth 🔎 @YoYInvestor]

This is Sahm Adrangi, Chief Investment Officer of Kerrisdale Capital Management, the firm that put out the short report on $BMNR this morning.

It is public knowledge that:

1. Mr. Adrangi was arrested on DUI and cocaine charges in the Hamptons in 2016 after crashing his BMW (mugshot attached below).

2. @KerrisdaleCap famously shorted $OKLO back in November 2024 when the stock was trading around $20 — it has since gained 575%.

3. @KerrisdaleCap famously shorted $MSTR back in March 2024 when the stock was trading around $170 — it has since gained 90%.

4. @KerrisdaleCap famously shorted $IONQ back in March 2025 when the stock was trading around $21 — it has since gained 266%.

These are publicly-accessible truths that anyone with an internet connection can observe. Looking at this firm’s professional track record, as well as the personal decision-making of their CIO, I can’t bring myself to take them seriously. This short report was one of the most juvenile, non-substantive pieces of equity “research” I have ever read. I’d expect better from a Yale grad, but their results have been nothing but disappointing. I’d encourage everyone to take what they have to say with a grain of salt.

$BMNR @fundstrat @BitMNR @amitisinvesting

[Brian Armstrong @brian_armstrong]

Happy ETH all time high to all those that celebrate!

[Blake Rocha @MrFourToEight]

This has got to be one of my best, most accurate calls ever.

Bitcoin then: $15.9k
Bitcoin today: $121k

🏆🏆🏆🏆🏆🏆🏆🏆

[Dak @dakmonster46]

@TJTheWheelDeal Interested to see your longs. You used to post them more

[Dak @dakmonster46]

@CryptoA40672341 Did you over leverage yourself?

[Kab X 🇺🇸 @KabraxFX]

Here are my thoughts on $HIMS 👇

1) Original shareholders, prior to any such knowledge of the original partnership, were always here because of the disruption $HIMS was causing to the Big Pharma industry through compounding. Our fight was always against Big Pharma, not to join them. This IS the thesis.
2) The Semaglutide provided by $HIMS has been the same before the shortage ended in February. If it was safe then, it is safe now - the suppliers did not change.
3) As part of 503b Pharmacy compounding standards, quality and verification of the APIs used are vetted at nearly every step of the process to ensure the highest quality production of their compounds.
4) $NVO partnered with $HIMS likely in an attempt to pressure $HIMS to drop selling personalized doses - essentially, "if you have our product, now you don't need to offer yours."
5) After further pressure to end personalized compounding, $NVO dissolved the partnership with $HIMS.
5) @AndrewDudum never claimed $HIMS would stop selling personalized doses, but will be up to the provider's discretion. This means it is not based on any limitation of company policy or selling guidelines.
6) $HIMS legal teams have made it clear they believe personalized doses make their distribution legal, and this has yet to be challenged in court.
7) It is strange that $NVO has not filed a lawsuit in tandem with the release of their statement. I do not believe a legal team of $NVO's stature would be so unprepared for this break in partnership that they didn't also have a lawsuit ready to go.
8a) $HIMS was never just a GLP-1 story, as we always say. They still have upwards of 14 verticals all with an ARR of over $100million each.
8b) $HIMS still has 11+ verticals to release, including Menopause and Testosterone this year.
9a) From the time we entered the partnership to the time it dissolved today, $HIMS is still in a more impressive position than before. We acquired ZAVA for international expansion.
9b) $HIMS now has gummies as a brand new product line for customers.
10) I am still bullish on $HIMS, as this is what the thesis was always about. 😎

[Vlad Tenev @vladtenev]

Some of you may have noticed that we're piloting a new mortgage benefit for our Robinhood Gold subscribers!

A mortgage is among the largest and most important financial transactions of your life, and we're proud to be offering one of the lowest rates on the market, plus $500 off closing costs, all in partnership with Sage Home Loans.

Let me know what you think ... I think you'll love it! 🏡

[Jrag.eth @Jrag0x]

👀 Surprise @RobinhoodApp announcement at EthCC on June 30th

[Tannor Manson @Futurenvesting]

$HOOD

Robinhood is one of the few fintechs that could outperform by simply doing nothing.

Why? Because the macro is shifting so heavily in their favor. Here are the structural tailwinds already working for them:

1. Self-directed investing is going mainstream. The trend toward DIY finance is accelerating, and Robinhood is already the go-to platform for millions of Gen Z and millennial investors.

2. The Great Wealth Transfer is underway. Over $84 trillion is set to move to younger generations who prefer mobile-first, low-fee platforms like Robinhood.

3. Crypto is becoming normalized, both through better regulation and growing acceptance in traditional portfolios. Robinhood, with early infrastructure and brand recognition, is well-positioned to benefit as crypto becomes a mainstream asset class.

4. InvestAmerica & financial inclusion policies are on the rise. Regulatory momentum is pushing for wider public market access, Robinhood’s mission fits that perfectly.

5. International retail access is still broken. Most countries don’t have a Robinhood equivalent. Their global expansion is a macro opportunity, not just a company plan.

Even without product innovation (an unheard-of concept for @vladtenev), Robinhood sits on top of multi-decade structural trends that are just starting to accelerate!

THAT'S VERY RARE.

[unusual_whales @unusual_whales]

Robinhood had its price target raised by stock analysts at Deutsche Bank Aktiengesellschaft from $70.00 to $85.00 yesterday.

Read more: https://t.co/098FfShX1D

[Justin Spittler @JSpitTrades]

We need to squash the idea that $HOOD ran up this week solely because of S&P 500 inclusion rumors.

1) First of all, HOOD is THE liquid leader. It's supposed to go up in bullish environments. Other leading names had good weeks. See $RBLX $RBRK $SPOT etc.

2) The market is super bullish. $QQQ closed up 2.1%. $SPY finished 1.7% higher. $IWM +3.3%. All three major indices finished the week at multi-month highs.

3) Animal spirits are back! $ARKK finished the week up 8.4%. Thematic stocks - space, nuclear, quantum - in particular had monster weeks.

Who do they think trades these names? Retail/degens. Where do many of them trade? Robinhood!

4) Robinhood provided excellent May 2025 operating data. Total assets jumped to $250b - an all time high. Options contracts traded on the platform increased by 5% versus April. An crypto trading volumes increased 30% month-over-month.

5) Bitcoin and crypto likely bottomed this week after flushing to just above $100k. This is good news for Robinhood's growing crypto arm

[Vlad Tenev @vladtenev]

Bitstamp is now part of Robinhood, adding a globally-scaled crypto exchange and our first-ever institutional crypto business.

Our work is just beginning.

[Nate Endicott @EndicottInvests]

I think the ZAVA acquisition might be one of the most overlooked but strategic moves $HIMS has made to date.

Let’s dive into everything I’ve dug up on Zava, the numbers, their footprint, and why this move is going to quietly position $HIMS as a true global healthcare platform.

This will be a long one — let’s go. 🧵

1. First — What is Zava?
Zava (originally known as DrEd) is a UK-based digital health company founded in 2010 by David Meinertz and Amit Khutti. It was one of Europe’s first major online healthcare providers.

📍 Headquarters: London, UK
🌍 Markets: UK 🇬🇧, Germany 🇩🇪, France 🇫🇷, Ireland 🇮🇪
💰 Estimated Revenue (FY’25): ~$35M–$45M (hard to pin down exact figures)
📈 Profitability: Operating near breakeven or slightly profitable
📊 Gross Margins: Estimated in the mid-70% range
🧾 Consultations in 2024: 2.3 million
👥 Active Customers: 1.3M+ across Europe

They’ve served 6M+ patients since inception — mostly in Europe. They were quiet but effective — which is exactly what $HIMS needed to break into Europe.

Note: These are end of 2023 financials. ~27.5M USD

Zava operates a hybrid digital healthcare model that combines in-house clinical services with strategic partnerships to deliver comprehensive care across Europe.

2. Zava’s Infrastructure & Tech Stack

Physical Infrastructure:
In-House Pharmacy:
-Zava owns and operates a registered pharmacy in the UK, staffed by licensed pharmacists and regulated by the General Pharmaceutical Council (GPhC). This facility handles direct prescription dispensing to patients.

Office Locations:
-Zava maintains office spaces in London and Dublin that serve as operational hubs for their services across the UK, Germany, France, and Ireland.

Laboratory Services:

Partner Laboratory:
-For diagnostic testing, Zava partners with The Doctors Laboratory (TDL), a UK-accredited medical lab responsible for sample analysis and test accuracy.

Technology Stack:

Custom EMR System:
-Zava uses a proprietary Electronic Medical Records system that manages clinical data, prescriptions, and medical questionnaires securely and efficiently.
Asynchronous Consultations:
-Patients complete online questionnaires, which are reviewed by Zava’s in-house medical team. This model enables flexible, non-real-time interactions while maintaining clinical rigor.

Service Model:
Zava operates a digital-first care model that minimizes the need for physical clinics while retaining control over clinical quality, fulfillment, and compliance. It’s a highly efficient blend of owned infrastructure, tech-enabled workflows, and trusted partnerships—perfectly aligned with $HIMS’ vertically integrated model.

3. The Acquisition Details
Announced: June 3, 2025
Deal Type: All-cash acquisition
Funding: 100% from $HIMS balance sheet (no dilution, no debt used)
Closing: Expected in H2 2025
Price: Not disclosed publicly, but likely under $400M based on Zava’s revenue + margins

4. Why Zava is Strategic for $HIMS
Here’s what Zava brings to the table immediately:

✅ Fully licensed operations in 4 European countries
✅ A multilingual clinical team + compliant EMR system
✅ Built-in prescription delivery infrastructure
✅ Over 1.3M active customers
✅ Familiarity with EU healthcare regulations
✅ High trust in local markets (UK reviews are solid)

This gives $HIMS a running start in Europe — without having to build everything from scratch.

Instead of spending years trying to enter the UK or Germany, they’re plugging into a system that already works.

5. A New Growth Engine: Europe 🌍
Until now, $HIMS has been 99% U.S.-centric.

This move opens up a whole new revenue stream and TAM. Let’s quantify it:

📈 EU digital health market = $55B by 2028
🇬🇧 UK weight loss market alone = $700M+
🇩🇪 Germany = Europe’s largest healthcare market ($500B+ spend annually)
👥 EU population = 448M
If $HIMS executes even remotely as well in Europe as it has in the U.S., this becomes a serious flywheel.

6. Financial Impact
Let’s connect the dots:
- Zava is expected to generate ~$35M–$45M in FY’25 revenue
- Likely breakeven or modestly profitable already
- $HIMS guiding for $2.35B in 2025 — without Zava revenue fully baked in
- Zava gives $HIMS a new growth engine in Europe — across weight loss, mental health, dermatology, and more
- $HIMS expects the acquisition to be accretive by 2026

Even if Zava contributes $50–75M in 2026 and scales to $200M+ over a few years, it starts to move the needle — especially paired with expanding U.S. revenue, GLP-1 acceleration, and new category launches.

7. Risks to Watch 🚨🚨
Let’s be real — no acquisition is risk-free.

Here are the key things to keep an eye on:

🚧 Regulatory Fragmentation:
Each European country has its own telehealth regulations. What works in the UK might not work in Germany or France. Local compliance isn’t plug-and-play.

🚧 Currency Exposure:
Operating across GBP and EUR adds FX risk and potential margin pressure, especially if inflation diverges by region.

🚧 Cultural + Operational Integration:
New markets, new teams, new processes. Even with similar values, aligning clinical standards and tech infrastructure across borders is no small feat.

🚧 Teladoc PTSD:
Some have already compared this to the $TDOC –Livongo deal, a flashy, expensive acquisition that ultimately led to billions in goodwill impairment and slowed momentum.

👉 Here’s why this is NOT that:

-This is a sub-$400M(Speculation), all-cash acquisition, not a bloated stock deal
-Zava expands $HIMS into new markets, not overlapping capabilities
- $HIMS has a clean track record of disciplined growth + product integration
-Zava is already operating profitably or near breakeven with an established customer base
-No promises of “game-changing synergies” — this is measured, tactical execution

Yes, there are risks — but they’re known, calculated, and outweighed by the potential upside.

8. Final Take
Zava isn’t some flashy acquisition to spike headlines.

It’s a strategic, disciplined land grab into an underserved market—using a tested model, a proven product stack, and a war chest most startups would kill for.

$HIMS has spent 7 years building a scalable platform.

Zava just gave them a new continent to run that playbook on.

What’s next? 👀
@AndrewDudum

[unusual_whales @unusual_whales]

Robinhood, $HOOD, has officially closed its $200 million acquisition of Bitstamp